JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 9, 2006; DOI: 10.1124/jpet.106.104141


0022-3565/06/3183-1265-1272$20.00
JPET 318:1265-1272, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.104141v1
318/3/1265    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moody, T. W.
Right arrow Articles by Jensen, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moody, T. W.
Right arrow Articles by Jensen, R. T.

CELLULAR AND MOLECULAR

In Vitro and in Vivo Antitumor Effects of Cytotoxic Camptothecin-Bombesin Conjugates Are Mediated by Specific Interaction with Cellular Bombesin Receptors

Terry W. Moody, Li-Chun Sun, Samuel A. Mantey, Tapas Pradhan, L. Vienna Mackey, Nieves Gonzales, Joseph A. Fuselier, David H. Coy, and Robert T. Jensen

Department of Health and Human Services, Center for Cancer Research, National Cancer Institute (T.W.M.) and Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (S.A.M., T.P., N.G., R.T.J.), National Institutes of Health, Bethesda, Maryland; and Department of Medicine, Peptide Research Laboratories, Tulane Health Sciences Center, New Orleans, Louisiana (L.-C.S., L.V.M., J.A.F., D.H.C.)

Most human tumors overexpress or ectopically express peptide hormone/neurotransmitter receptors, which are being increasingly studied as a means to selectively deliver cytotoxic agents. Although a number of peptide ligand-constructs demonstrate tumor cytotoxicity, the role of specific tumoral receptor interaction in its mediation is unclear. To address this question, we synthesized camptothecin (CPT) bombesin (Bn) analogs, in which CPT was coupled via a novel carbamate linker, L2 [N-(N-methyl-amino-ethyl)-glycine carbamate], that were chemically similar but differed markedly in their potency/affinity for human Bn receptors. We then examined their ability to interact with Bn receptors and cause in vitro and in vivo tumor cytotoxicity. CPT-L2-[D-Tyr6,beta-Ala11,D-Phe13,Nle14] Bn (6-14) (BA3) bound with high affinity and had high potency for all three human Bn receptor subtypes, whereas CPT-L2-[D-Tyr6,beta-Ala11, D-Phe13,Nle14] Bn (6-14) [D-Phe-CPT-L2-BA3] had >1400-fold lower affinity/potency. 125I-CPT-L2-BA3 but not 125I-D-Phe-CPT-L2-BA3 was internalized by Bn receptor subtype-containing cells. CPT-L2-BA3 displayed significantly more cytotoxicity than D-Phe-CPT-L2-BA3 toward NCI-H1299 lung cancer cells in both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide and clonogenic assays and more potently inhibited H1299 xenograft growth in nude mice. CPT-L2-BA3 was also metabolically more stable than its parent peptide and inhibited growth of a number of other tumor cell lines in vitro and in vivo. These results demonstrate that specific tumoral receptor interaction is important in mediating the ability of peptide ligand-cytotoxic constructs to cause cytotoxicity. Because many tumors overexpress Bn receptors, these results also demonstrate that CPT-L2-BA3 will be a useful agent for delivering receptor-mediated cytotoxicity to many different human tumors.


Received March 10, 2006; accepted June 8, 2006.

Address correspondence to: Dr. Terry W. Moody, Department of Health and Human Services/National Institutes of Health, National Cancer Institute, Office of the Director, Building 31, Room 4A48, 31 Center Drive, Bethesda, MD 20892. E-mail: moodyt{at}mail.nih.gov




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
P. A. Bunn Jr
Diseases Desperate Grown
J Natl Cancer Inst, April 16, 2008; 100(8): 520 - 521.
[Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya
International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States
Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
D. Cornelio, R Roesler, and G Schwartsmann
Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy
Ann. Onc., September 1, 2007; 18(9): 1457 - 1466.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.